Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HEXD | Q8WVB3 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13771902 | 0.90 | HPGD (0.48) | HPGDUSP2TSHRSMN1; SMN2KMT2A | |
| SCHEMBL13771909 | 0.88 | MAPT (0.43) | HPGDPOLB | |
| SCHEMBL4133470 | 0.85 | AR (0.47) | — | |
| SCHEMBL4132662 | 0.84 | AR (0.47) | — | |
| SCHEMBL4133498 | 0.84 | AR (0.47) | — | |
| SCHEMBL4152252 | 0.82 | AR (0.50) | — | |
| SCHEMBL4147368 | 0.82 | AR (0.50) | — | |
| SCHEMBL4141069 | 0.82 | AR (0.47) | SMN1; SMN2KMT2AALDH1A1MEN1LMNA | |
| SCHEMBL4146145 | 0.81 | AR (0.48) | — | |
| SCHEMBL13771910 | 0.81 | AR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192202-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-30 | — | — | US | disclosed |
| US-20090192202-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-30 | — | — | US | disclosed |
| US-7507860-B2 | Androgen modulators | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507860-B2 | Androgen modulators | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070197641-A1 | Androgen modulators | HU LAIN-YEN | 2007-08-23 | — | — | US | disclosed |
| US-20070197641-A1 | Androgen modulators | HU LAIN-YEN | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197641-A1 | Androgen modulators | AR, NR5A1, SHBG | HPGD 768/4885USP2 2651/4885TSHR 364/4885 |
| US-20090192202-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | HPGD 768/4885USP2 2651/4885TSHR 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.